I was hoping cash burn might decrease in this current quarter, since the March quarter had included a sizeable $5m milestone payment on the onset of patient dosing. Interesting that Coppo sees it increasing.
My cursory analysis had led me to thinking a deal with up-front cash for working capital could come before a CR is needed. Coppo is now leaning to a CR.
I’d go with Coppo here, team. I would assume they have crunched more numbers than me.
research reports and media, page-2751
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 29.5¢ | $102.6K | 339.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25493 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 10254 | 6 |
View Market Depth
| Last trade - 13.55pm 17/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |